Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 18/20 | 0.60 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.60 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14710431 | 0.88 | LPAR1 (0.66) | LPAR1LPAR3LPAR2USP36 | |
| SCHEMBL14711013 | 0.86 | LPAR1 (0.61) | LPAR1LPAR3LPAR2 | |
| SCHEMBL14711353 | 0.83 | LPAR1 (0.68) | LPAR1LPAR3LPAR2 | |
| SCHEMBL14710223 | 0.83 | LPAR1 (0.68) | LPAR1LPAR3LPAR2 | |
| SCHEMBL14711340 | 0.83 | LPAR1 (0.60) | LPAR1LPAR3LPAR2 | |
| SCHEMBL14711734 | 0.83 | LPAR1 (0.54) | LPAR1LPAR3 | |
| SCHEMBL14711602 | 0.83 | LPAR1 (0.54) | LPAR1LPAR3 | |
| SCHEMBL14711599 | 0.82 | LPAR1 (0.61) | LPAR1LPAR3LPAR2 | |
| SCHEMBL13195932 | 0.81 | LPAR1 (0.60) | LPAR1LPAR3LPAR2 | |
| SCHEMBL14711406 | 0.81 | LPAR1 (0.78) | LPAR1LPAR3LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | LPAR1 1/4885LPAR3 5/4885LPAR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.